Rosiglitazone is a potential treatment for atherosclerosis, in which it regulates angiotensin-mediated inflammatory responses in VSMCs. The targeted signaling pathways by rosiglitazone are ERK1/2/TLR4/IP-10/PKC/NF-kB. Here, TLR4 is linked to atherosclerosis.